Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peptide-pulsed dendritic cell vaccine + Poly-ICLC
- Development stage
- Unknown
- Lead developer
- Medical University of South Carolina
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, Peptides
- Administration
- Intradermal, Intramuscular
01
Overview
This investigational cancer vaccine consists of autologous dendritic cells pulsed with three HLA-A2-restricted tumor-associated peptides—human telomerase reverse transcriptase (hTERT, TERT572Y), carcinoembryonic antigen (CEA; Cap1-6D), and survivin (SRV.A2)—administered in combination with Poly-ICLC (Hiltonol), a synthetic double-stranded RNA and Toll-like receptor 3 (TLR3) agonist. Developed by researchers at the Medical University of South Carolina under the leadership of Dr. Carolyn Britten, the therapy is designed to treat metastatic or locally advanced unresectable pancreatic adenocarcinoma. The dendritic cells act as professional antigen-presenting cells to prime the immune system, while Poly-ICLC serves as a potent adjuvant to enhance the magnitude and quality of the tumor-specific T-cell response.
- Other names
- Poly-ICLC and Peptide-pulsed DC VaccinehTERT/CEA/survivin peptide-pulsed dendritic cell vaccine
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)γδ TCR (T-cell receptor)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on peptide-pulsed dendritic cell vaccine + Poly-ICLC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peptide-pulsed dendritic cell vaccine + Poly-ICLC.